BMS Reports P-III (COMMANDS) Study Results of Reblozyl (luspatercept-aamt) for Myelodysplastic Syndromes
Shots:
- The P-III (COMMANDS) study evaluating Reblozyl vs epoetin alfa in patients with anemia due to very low, low- or intermediate-risk (IPSS-R) MDS in patients who are RBC transfusion-dependent & were ESA naïve. The therapy is being developed & commercialized through global collaboration with Merck
- The trial met its 1EPs i.e., clinical improvement in red blood cell transfusion independence (RBC-TI) with concurrent Hb increase. The safety results were consistent with the safety profile of Reblozyl prior reported in the (MEDALIST) study & no new safety signals were observed
- The company will work with investigators to present detailed results at an upcoming medical meeting & discussed with health authorities
Ref: Businesswire | Image: BMS
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
